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Abstract
Background: The major histocompatibility complex (MHC) is essential for human immunity and
is highly associated with common diseases, including cancer. While the genetics of the MHC has
been studied intensively for many decades, very little is known about the epigenetics of this most
polymorphic and disease-associated region of the genome.
Methods: To facilitate comprehensive epigenetic analyses of this region, we have generated a
genomic tiling array of 2 Kb resolution covering the entire 4 Mb MHC region. The array has been
designed to be compatible with chromatin immunoprecipitation (ChIP), methylated DNA
immunoprecipitation (MeDIP), array comparative genomic hybridization (aCGH) and expression
profiling, including of non-coding RNAs. The array comprises 7832 features, consisting of two
replicates of both forward and reverse strands of MHC amplicons and appropriate controls.
Results: Using MeDIP, we demonstrate the application of the MHC array for DNA methylation
profiling and the identification of tissue-specific differentially methylated regions (tDMRs). Based on
the analysis of two tissues and two cell types, we identified 90 tDMRs within the MHC and describe
their characterisation.
Conclusion: A tiling array covering the MHC region was developed and validated. Its successful
application for DNA methylation profiling indicates that this array represents a useful tool for
molecular analyses of the MHC in the context of medical genomics.
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The major histocompatibility complex (MHC) is a 4 Mb
region on the short arm of human chromosome 6 [1]. It
is one of the most gene-dense regions of the human
genome and it is associated with many complex diseases
including infectious, autoimmune and inflammatory dis-
eases as well as cancer. In many cases, their aetiologies are
polygenic and involve genetic, epigenetic and environ-
mental factors. Although past studies have generated
extensive data for the genetics of the MHC resulting in
important contributions to medicine [2-4] further studies
are necessary to improve our understanding of the causes
of such diseases. Because of its central role in so many
complex diseases, elucidating the epigenetic code of the
MHC can be expected to be highly beneficial for biomed-
ical research.
Epigenetics is a term used to describe mitotically and, in
some cases, meiotically heritable states of gene expression
that are not due to changes in the DNA sequence [5]. The
best-studied epigenetic marks are DNA methylation and
histone modifications. The latter are post-translational
modifications and occur at specific positions within the
amino-terminus of histone tails. They include acetylation,
methylation, phosphorylation, ubiquitination and other
modifications and are correlated with chromatin accessi-
bility and transcriptional activity or repression [6,7]. DNA
methylation on the other hand involves the addition (or
removal) of methyl groups at the carbon-5-position of
cytosine. In mammals this occurs predominantly in the
context of cytidine-guanosine (CpG) dinucleotides [8],
but non-CpG methylation has also been reported in cer-
tain cell types and is common in plants [9-11]. In mam-
malian somatic cells, about 70% of CpGs are methylated
(hypermethylated) and these sites predominantly occur
in repetitive DNA elements, satellite DNAs, non-repetitive
intergenic DNA and exons [8]. In contrast, the CpGs
located in the estimated 29,000 CpG islands, found span-
ning the promoters and 5'-untranslated regions (5'-UTRs)
of about 60% of human genes are largely unmethylated
(hypomethylated) [8]. DNA methylation can regulate
transcription either directly by interfering with transcrip-
tion factor binding or indirectly via methyl binding
domain (MBD) containing proteins resulting in changes
in chromatin architecture [12,13]. Recently, non-coding
RNAs (ncRNAs) have been recognised as an additional
component associated with epigenetic modulation and
have been reported to be involved in X-chromosome inac-
tivation, chromatin structure, DNA imprinting and DNA
demethylation [14].
Emerging evidence suggests that epigenetic events are
associated with the regulation of MHC gene expression. It
has been shown, for instance, that the MHC class II trans-
activator (CIITA) and the regulatory factor X (RFX) pro-
teins serve as focal points for recruiting histone modifying
enzymes to MHC class II promoters, whereby CIITA itself
is regulated by DNA methylation, histone modifications
and ncRNAs [15,16]. Treatment of melanoma and
esophageal cell lines with the DNA methylation inhibitor
5-aza-2-deoxycytidine led to restoration of MHC class I
expression (which is suppressed in these cell lines), impli-
cating DNA methylation in expression of MHC class I
genes [17-19].
As part of the Human Epigenome Project (HEP), about
2.5% of the MHC region has been analysed for DNA
methylation [20]. This study has demonstrated that a sig-
nificant proportion (10%) of the MHC loci analysed show
tissue-specific DNA methylation profiles. Such regions
have been termed tissue-specific differentially methylated
regions (tDMRs) and are thought to contain elements
involved in tissue-specific gene expression [21].
To facilitate a more comprehensive epigenetic analysis of
the MHC, we have constructed a tiling array that covers
the entire 4 Mb of the MHC at 2 kb resolution. This array
is an economical alternative to commercial arrays and can
be used for: i) ChIP-on-chip studies, investigating DNA/
protein interactions [22]; ii) DNA methylation studies,
investigating tissue- or disease-specific DNA methylation
profiles [23,24]; iii) array comparative genomic hybridi-
zation (aCGH), investigating copy number variations
(CNVs) [25,26]; and finally, for expression studies, inves-
tigating both coding and non-coding RNAs.
Here we describe the generation and properties of an array
for the human MHC and we show how it can be used for
DNA methylation studies, particularly for the identifica-
tion of DMRs.
Methods
Design, generation and quality control of the MHC tiling 
array
The array was designed to cover the entire MHC region as
a minimally overlapping tile path, with appropriate con-
trols. A total of 1747 overlapping plasmid clones were
used to generate the array. Of those, 1662 clones (average
insert size 2 kb) were picked from the HapMap chromo-
some 6 library [27] and 85 clones were generated by clon-
ing gap-spanning PCR amplicons (average insert size 332
bp). Some repeat-rich regions (about 12 kb in total)
proved to be refractory to PCR amplification and are
hence missing from the array. Therefore, the total cover-
age represents 99.67% of the MHC region. In addition, we
generated and included 43 PCR-derived clones as con-
trols, covering: i) CpG islands of BRCA1, GSTP1, RARB2
and MLH1 genes [28]. ii); imprinted regions (H19, IGF2,
KvDMR1, HSIGF2G, IGF2RDMR2 and DMR0) [29]; iii)
gene poor regions of chromosome 6; iv) matrix attach-Page 2 of 16
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associated DNA of the PRM2 gene [30]; vi) promoter
regions of the GAPDH and IRF1 genes; vii) replication ori-
gin of the LB2 gene; vii) replication origin-lacking region
of the β-globin locus; and viii) DNAase I-hypersensitivity
sites of the β-globin locus control region. Ten genes from
the Arabidopsis genome (spotted in replicates, distributed
across the array) that can be used to assign DNA barcodes
as internal controls were also included. In addition, 192
Cy3 spots were printed on each array that can be used for
calibration and orientation. Except for the Cy3 spots,
none of other controls were used for the analysis
described here but may be useful for other types of analy-
ses. MHC probe coordinates and primer sets used for the
generation of gap-spanning and control clones can be
provided upon request.
Double-stranded amino-linked amplicons were generated
from each clone using vector-specific PCR in 50 mM KCl,
5 mM Tris pH 8.5 and 2.5 mM MgCl2 (10 min at 95°C;
followed by 35 cycles of 95°C for 1 min, 60°C for 1.5
min, 72°C for 7 min; and a final extension of 72°C for 10
min – Forward primer 5'-CCCAGTCACGACGTTG-
TAAAACG-3', Reverse primer 5'-AGCGGATAACAATT-
TCACACAGG-3'). In order to generate strand-specific
array probes, two separate PCR reactions were performed
for each clone, in one case using a 5'-aminolinked primer
for the forward strand, and in the other case, for the
reverse strand. After quality assessment of the products by
gel electrophoresis, spotting buffer was added directly to a
final concentration of 250 mM sodium phosphate pH 8.5,
0.00025% w/v sarkosyl, 0.1% sodium azide, and the
products were filtered (Multiscreen-GV filter plates, Milli-
pore). Arrays were spotted onto amine binding slides
(CodeLink, GE Healthcare) at 20–25°C, 40–50% relative
humidity. After an overnight incubation in a humid
chamber, the slides were blocked (1% ammonium
hydroxide for 5 min, followed by 0.1% SDS for 5 min)
and denatured (95°C ddH2O for 2 min), rinsed in ddH2O
and dried by centrifugation for 5 min at 250 × g. Thus, the
covalently attached strand-specific probes were rendered
single-stranded in preparation for hybridization.
The final array therefore comprises 7832 features (2 ×
1747 MHC forward probes, 2 × 1747 MHC reverse
probes, 4 × 43 human control probes, 480 Arabidopsis
control probes and 192 Cy3 dye controls). Resequencing
of 240 probes (15% of total) identified 7 probes that
failed to match to the expected reference sequences. Aliq-
uots of all probes can be made available upon request for
further QC analysis. From this partial analysis, we extrap-
olate that about 97% of the probes are correct and should
be informative.
DNA samples
Human DNA samples from healthy individuals were
obtained from AMS Biotechnology (Oxon, UK), Analyti-
cal Biological Services (Wilmington DE, USA) and from
the MHC Haplotype Project [31]. Samples included DNA
extracted from two tissues (liver and placenta) and 2 cell
types (CD8+ lymphocytes and sperm). Additional infor-
mation on those samples is summarized in Table 1.
Methylated DNA immunoprecipitation (MeDIP)
MeDIP was performed as described by Weber and col-
leagues [23] with the following modifications. DNA sam-
ples (2.5 μg) were sheared into fragments of average size
of 600 bp using a sonicator (Virtis). Fragmented DNA was
incubated with 1 × buffer 2 (New England Biolabs, UK),
10 × BSA (NEB, U.K.), 1.2 μl dNTP mix (10 mM each)
(Abgene, UK), 3 Units of T4 DNA polymerase (New Eng-
land Biolabs, U.K.) and distilled water to a final volume
of 120 μl for 20 minutes at 12°C. The reaction was
cleaned up using a Zymo-5 kit (Genetix, U.K.) according
to the manufacturer's instructions but the final elution
was done in 30 μl of TE buffer (10 mM Tris-HCl pH 8.5, 1
mM EDTA). The adaptors JW102 (5'-gcggtgacccgggagatct-
gaattc-3') and JW103 (5'-gaattcagatc-3') were ligated to
the cleaned-up DNA by incubation overnight at 16°C in a
reaction containing 40 μl adaptor mix (50 μM), 6 μl T4
DNA ligase 10 × buffer (NEB, UK), 5 μl T4 DNA ligase
Table 1: Tissues and cell types used in this study
Index Tissue Replicate Age (yrs) Sex Ethnicity Supplier
1 Liver 1 37 M Caucasian ABS, Wilmington, DE, USA
2 Liver 2 29 M Caucasian BCI, Haywatd, CA, USA
3 Placenta 1 29 (mother) F Caucasian ABS, Wilmington, DE, USA
4 Placenta 2 31 (mother) F Caucasian ABS, Wilmington, DE, USA
5 Sperm 1 20–49 M Caucasian MHC Haplotype Project [31]
6 Sperm 2 20–49 M Caucasian MHC Haplotype Project [31]
7 T-cells CD8 1 41 M Caucasian ABS, Wilmington, DE, USA
8 T-cells CD8 2 27 F African American ABS, Wilmington, DE, USA
ABS: Analytical Biological Services [50]
BCI: BioChain Institute [51]Page 3 of 16
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ume of 100 μl. DNA was cleaned up as described above.
To fill in the overhangs, the sample DNA was incubated at
72°C for 10 minutes with 1 μl dNTP mix (10 mM each),
5 μl 10 × AmpliTaq Gold PCR buffer (Applied Biosystems
– Roche), 3 μl MgCl2 (250 mM), 5 U AmpliTaq Polymer-
ase and distilled water to a final volume of 50 μl. DNA was
cleaned up as described above. 50 ng of the ligated DNA
sample was set aside as the input fraction. 1.2 μg of the
ligated DNA sample was denatured for 10 minutes at
100°C and then placed on ice for 5 minutes. Immunopre-
cipitation was performed in 1 × IP buffer (20 mM sodium
phosphate pH 7, 280 mM NaCl, 0.1% Triton X-100) and
3 μl of 5-MeC-mAb (Eurogentec) with incubation at 4°C
with slow rotation for 2 hours. 10 μl Dynabeads (M-280
Sheep anti-Mouse IgG – 6.7 × 108 beads/ml) (Dynal Bio-
tech) were washed in 1 × IP buffer according to the man-
ufacturer's instructions and added to the DNA-antibody
mixture and then incubated at 4°C with slow rotation for
2 hours. The Dynabead-Ab-DNA mixture was washed
three times with 500 μl IP buffer and finally resuspended
in 100 μl of proteinase K buffer (10 mM Tris-HCl pH 7.8,
5 mM EDTA, 0.5% SDS). 1 μl of proteinase K (50 U/ml)
(Roche Diagnostics) was added and incubated at 50°C for
2 hours with rotation. The sample was cleaned up using a
Zymo kit-5 (using 700 μl binding buffer). The DNA con-
centration was determined with a NanoDrop (using 1
OD260 = 33 μg) and diluted to 1 ng/μl. Two separate
amplifications were performed for the respective IP and
input fractions using ligation-mediated PCR (LM-PCR)
[32]. LM-PCR was performed in a final volume of 50 μl
containing 10 μl distilled water, 10 μl Advantage-GC
buffer (BD Biosciences), 10 μl GC-melt (BD Biosciences),
3.1 μl 25 mM Mg(OAc)2, 5 μl JW-102 primer (10 μM), 1.4μl dNTPs (10 mM each), 1 μl Advantage-GC polymerase
(BD Biosciences) and 10 μl DNA (1 ng/μl). Reaction con-
ditions were as follows: 1 cycle at 95°C for 2 minutes for
initial denaturation, 20 cycles at 94°C for 30 seconds,
68°C for 3 minutes and 1 cycle at 68°C for 10 minutes.
After LM-PCR, the reactions were cleaned up using a
QIAquick PCR Purification kit (Qiagen) and eluted with
50 μl of water (pre-heated to 50°C).
Real-time PCR of MeDIP samples
For MeDIP validation, we performed quantitative real-
time PCR (qRT-PCR), using an ABI Prism 7300 Sequence
Detection System and 30 ng of input and immunoprecip-
itated DNA (after LM-PCR). For each qRT-PCR reaction
(total volume of 13.5 μl) we used 6.5 μl SYBR Green PCR
master mix (Eurogentec) and 2.5 μl primer mix (1.5 μM
each.). Reaction conditions were as follows: 1 cycle at
50°C for 2 minutes, 1 cycle at 95°C for 10 minutes, 40
cycles at 95°C for 15 seconds and 1 cycle at 60°C for 1
minute. Reactions were done in triplicates. To evaluate the
relative enrichment of target sequences after MeDIP, we
normalized (for each amplicon tested) the Ct of the
MeDIP fraction to the Ct of the input (ΔCt). Subsequently
we normalised the ΔCt of each target sequence to the ΔCt
of an unmethylated control sequence (ΔΔCt). Finally, we
calculated the enrichment . Primer sequences
can be provided upon request.
DNA labelling and microarray hybridization
Fluorescent labelling was performed using a modified
Bioprime labelling kit (Invitrogen) in a 130.5 μl reaction
containing 100 ng DNA, 15 μl dNTP mix (2 mM dATP, 2
mM dTTP, 2 mM dGTP, and 0.5 mM dCTP), and 1.5 μl
Cy5/Cy3 dCTP (1 mM) (Perkin Elmer). The reactions
were purified using Micro-spin G50 columns (Pharmacia-
Amersham) in accordance with the manufacturer's
instructions. Reference and test samples were combined
and precipitated with 55 μl of 3 M sodium acetate (pH
5.2) in 2.5 volumes of ethanol with 135 μg human Cot1
DNA (Invitrogen). The DNA pellet was resuspended in
hybridization buffer containing 50% deionized forma-
mide, 10% dextran sulphate, 10 mM Tris-HCl (pH 7.4), 2
× SSC, 0.1% Tween-20, and 200 μg yeast tRNA (Invitro-
gen). Hybridization was performed for 24 hours at 37°C
on a MAUI hybridization platform. Finally, the arrays
were washed serially in solution 1 (2 × SSC, 0.03% SDS)
for 5 minutes at room temperature, in solution 1 for 5
minutes at 60°C, four times in solution 2 (2 × SSC) for 20
minutes at room temperature, in solution 3 (PBS, 0.05%
Tween20) for 10 minutes at room temperature and finally
in HPLC water for 10 minutes at room temperature. Sub-
sequently the arrays were dried and scanned using a
ScanArray Express HT scanner (PerkinElmer).
Microarray data analysis
For each sample we analysed two biological replicates. All
hybridizations were performed with fluorochrome-
reversed pairs of two-colour labelled probes (dye swaps).
For the purpose of this analysis we treated the forward and
reverse probes as replicates. Hence, for each sample tested,
we obtained 16 measurements derived from quadrupli-
cate spots on 4 array hybridizations (two biological repli-
cates plus dye swaps). Fluorescence intensities were
determined using the ScanArray Express software (Perk-
inElemer). Fusion of dye-swap and biological replicate
results and subsequent analyses were performed using
Bioconductor [33]. For each probe, log-ratios were nor-
malised within arrays using a Local Linear Regression
(loess) [34] whereas average intensities were normalised
between arrays [35] leaving previously normalised ratios
unchanged. Dye-swapped samples and biological repli-
cates were defined in a design matrix. Subsequent analyses
were performed according to the design matrix by fitting a
( )E Ct= 2ΔΔPage 4 of 16
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squares, allowing for correlation between the four dupli-
cated spots [36]. Finally ranking the features according to
their evidence of discrepancy between effects defined in
the design matrix has been performed by using empirical
Bayes method [37]. The array data described here have
been deposited in ArrayExpress under accession numbers
E-TABM-471 (experiment) and A-MEXP-1163 (array
design).
tDMR feature analysis
The Application Programme Interfaces (API) was used to
extract genomic features associated with tDMR coordi-
nates from the Ensembl functional genomics dataset
(NCBI36). The whole of chromosome 6 was scanned
using a 2 kb window and 1 kb steps (i.e. moving the win-
dow from the start to the end of the chromosome, shifting
each time by 1 kb). For each window, the number of each
type of feature within the bounds of the window was
counted. This way, a discrete probability distribution was
generated, which determines, for a randomly selected
window, how likely it would be to have a certain number
of features. Windows that overlapped a gap in the assem-
bly were ignored to avoid biasing the result. For each DMR
and for each type of feature, the number of features that
were found and their probability distribution were used to
calculate (using 95% confidence interval) if the DMR was
enriched for that feature.
Bisulphite sequencing
Genomic DNA was subjected to sodium bisulphite con-
version using the EZ DNA methylation Kit (Genetix, U.K.)
according to the manufacturer's instructions. Primer
design, bisulphite-PCR and sequencing were carried out
as described by Rakyan et al., 2004 [20]. Primer sequences
can be provided upon request. Absolute DNA methyla-
tion values were estimated from signal ratios of the corre-
sponding sequence traces using the ESME software [38].
Results
MHC tiling array
In order to facilitate analyses of the regulation and func-
tion of genes and control elements within the MHC
region on chromosome 6, we constructed a tiling array
that encompasses the almost (99.67%) complete 4 Mb
region at 2 kb resolution. As described in the Methods sec-
tion, the array entails a total of 7832 features (7640
probes and 192 Cy3 control spots) of which 97% are esti-
mated to be informative following the quality control
described under Methods. The array can be requested
from the Microarray Facility at the Wellcome Trust Sanger
Institute [39].
Generation of DNA methylation profiles
To demonstrate the utility of the MHC tiling array, we first
generated comprehensive DNA methylation profiles in
conjunction with the Methylated DNA Immunoprecipita-
tion (MeDIP) assay [23]. Using an antibody that specifi-
cally recognises 5-methylcytosine, we
immunoprecipitated the methylated fraction of sheared
genomic DNA from two tissues (liver and placenta) and
two cell types (CD8+ lymphocytes and sperm). MeDIP
and input fractions were amplified by ligation-mediated
PCR (LM-PCR) [32]. We validated MeDIP by performing
qRT-PCR (see Methods) to test the enrichment of regions
with varying CpG densities for which the methylation sta-
tus was known from the Human Epigenome Project
[20,40]. Figure 1 shows that following MeDIP, methylated
regions are enriched approximately proportionally to
their CpG densities and no significant enrichment irre-
spective of CpG density is observed for unmethylated
regions. Using a threshold of ≥5-fold enrichment, the
MeDIP assay is therefore sensitive for regions of ≥1% CpG
density.
Using this threshold (actual enrichment range was 5–80
fold), we generated DNA methylation profiles of the
entire MHC for CD8+ lymphocytes, sperm, liver and pla-
centa (Figure 2). Control hybridizations assessing biolog-
ical replicates (R2 > 0.97), dye-swaps (R2 > 0.72) and LM-
PCR (R2 > 0.88) showed that any bias introduced by these
factors was within an acceptable range (Additional File 1).
At this (megabase) resolution, three main observations
can be made: (i) The overall profiles correlate significantly
(0.83 < R2 < 0.93), suggesting few or no large-scale (>100
Kb) differences in DNA methylation, except perhaps in
liver, where some regions appear to be lower in methyla-
tion than in other tissues. (ii) As expected from the result
shown in Figure 1 (although CpG density was analysed
here), the profiles correlate very well with C+G content,
clearly demarcating the boundaries of the MHC class I, III,
II and extended class II regions. (iii) The profiles further
show the vast improvement in coverage compared to the
253 amplicons, analysed as part of the Human Epige-
nome Project [20].
Compared to most commercial and custom arrays, our til-
ing array also contains repeat elements, allowing such
sequences to be analysed as well if desired. Figure 3a
shows the distribution and frequency of repeat sequences
within the probes on the array. About 9% of the probes
have low (0–5%) repeat content and around 11% have
high (95–100%) repeat content. The majority (80%) of
probes have a random repeat content ranging from 6–
94%. For studies that are not designed to interrogate
repeat sequences (as the study presented here) we show
that repeat sequences can be efficiently blocked by the
addition of human Cot1 DNA during hybridization (Fig-Page 5 of 16
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Cy5 channel for two hybridizations, one with and the
other without Cot1 DNA. In the presence of Cot1 DNA,
the intensities of repeat-containing probes are clearly
reduced to the same level detected for repeat-free probes,
indicating that undesired repeat signals can be blocked
and that the unique parts of repeat-containing probes
remain to be informative and can be kept for further anal-
ysis.
Identification and characterisation of tDMRs
For the identification of tDMRs, we performed pair-wise
comparisons (six in total: CD8+ lymphocytes versus pla-
centa, liver versus placenta, placenta versus sperm, CD8+
lymphocytes versus sperm, liver versus sperm, and liver
versus CD8+ lymphocytes) of the array-derived DNA
methylation profiles. At 2 kb, the probe resolution was
not high enough to determine if more than one tDMR was
contained within a probe or if positive, adjoining probes
were part of the same tDMR. Therefore, each differentially
methylated probe was considered to be a separate tDMR.
According to this definition, we identified a total of 90
tDMRs of which 35 were present in more than one com-
parison (Figure 4; Additional File 2). For validation, we
randomly selected six tDMRs (irrespective of their
genomic functionality) and subjected them to independ-
ent methylation analysis using bisulphite DNA sequenc-
ing. Figure 5 shows their methylation status based on
comparison of their respective MeDIP array profiles (a)
and their absolute methylation values based on bisulphite
sequencing (b). The characteristics of these tDMRs are
shown in Table 2. In all six cases, the bisulphite sequenc-
ing results were consistent with the array data, indicating
that that the array is suitable for the identification of
tDMRs.
According to the pair-wise analyses, sperm is most fre-
quently differentially methylated which agrees with the
findings of the Human Epigenome Project [40]. The
majority of tDMRs identified in sperm are hypomethyl-
Correlation between enrichment after MeDIP and CpG densityFigure 1
Correlation between enrichment after MeDIP and CpG density. Control sequences that are methylated, unmethyl-
ated or lack CpG sites were selected from HEP [49]. MeDIP was done using liver genomic DNA. The relative enrichment of 
the MeDIP versus input fractions was calculated based on qRT-PCR data. The graph shows a specific and efficient enrichment 
of methylated over unmethylated fractions. The error bars indicate the variance of two independent measurements. Methyl-
ated amplicons display an approximately linear dependency on CpG density (CpG density equals the number CpG sites per 
amplicon divided by the length of the amplicon multiplied by 100).Page 6 of 16
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placenta-sperm comparison; 93% of tDMRs in CD8-
sperm comparison; 32% of tDMRs in liver-sperm compar-
ison). Notable exceptions are the tDMRs identified in the
complement region which seem to be less methylated in
liver than any of the other samples (Figure 4; Additional
File 2).
Next, we correlated the tDMRs with gene expression using
data publicly available from the Genomics Institute of the
DNA methylation profiles of the MHCFigure 2
DNA methylation profiles of the MHC. For each of the four samples tested (CD8+ lymphocytes, liver, placenta, sperm), 
the log2 signal ratios (MeDIP/input) were uploaded as individual tracks to the UCSC genome browser using the 'smooth' func-
tion. Regions enriched or depleted in DNA methylation are shaded in black and grey, respectively. Also shown are the loca-
tions of HEP amplicons [49] and a track of the C+G content (the darker the shading, the higher the C+G content). For 
orientation, the approximate positions of the MHC class I, II and II sub-regions and some landmark genes are indicated.Page 7 of 16
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Distribution and suppression of repeat sequencesFigure 3
Distribution and suppression of repeat sequences. a) Distribution (in 5% bins) and frequency of repeat sequences within 
probes on the array. b). Suppression of repeat-specific signal using Cot1 DNA. Two independent hybridizations were carried 
out using genomic DNA extracted from CD8+ lymphocytes. In both experiments total DNA was labelled with Cy5 dye. Only 
in one of them unlabelled Cot1 DNA was added. In the non-Cot1 hybridization, Cy5 intensity increases almost linearly with 
repeat density until it reaches a plateau (around 25,000 Cy5 intensity). In the presence of Cot1 DNA, Cy5 intensity of highly 
repetitive probes is comparable to those of repeat-free probes. Repeats were defined based on the 'All repeats' track in 
Ensembl browser [43].
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Table 2: Genomic features of non-redundant tDMRs
chr6 coordinates 
(NCBI_35)
TSS CTCF H4K20 
me1
PolII H3K4 
me2
H3K36 
me3
H3K4 
me3
DnaseI H3K4 
me1
CpG 
island
ECR H2AZ repeats % CpG %
1 29823989–29826356 x x x x x 28.63 2.94
2 30000805–30003606 x x x 12.6 9.28
*3 30228982–30231712 26.44 2.64
*4 30247370–30249040 x x x x 4.73 9.1
*5 30565890–30568365 x x x x 11.95 4.77
6 30721858–30724158 x x 5.91 10.52
7 30731648–30734384 42.71 2.27
8 30891136–30893651 95.08 5.24
9 31709197–31711626 x 79.93 5.01
*10 31803609–31806450 x x x x 0 2.88
11 31841070–31843352 x 0 11.05
12 32020686–32023216 x 18.4 5.61
13 32056738–32058031 x 6.57 3.935
*14 32067481–32068550 0 3.09
*15 32071709–32072864 0 5.61
16 32073608–32074514 0 5.02
17 32074474–32074660 13.67 3.97
*18 32077678–32079121 0 5.35
*19 32081199–32081780 19.53 5.4
20 32088659–32090434 0 3.685
*21 32088718–32090526 0 3.41
*22 32090749–32092076 1.96 4.22
23 32092057–32093147 0 2.38
24 32094350–32095101 100 1.33
25 32098656–32099323 100 3.59
26 32099573–32100214 0 3.875
*27 32104734–32105602 0 5.29
*28 32107212–32107398 0 5.35
29 32109195–32110435 9.995 5.6
*30 32110416–32111859 19.53 5.4
31 32115381–32116535 x 0 7.27
32 32119000–32120024 x 0 7.61
33 32223988–32226638 x x 4.19 11.09
34 32659407–32660508 x x x 9 5
35 32817677–32820582 20.44 2.96
36 32836042–32838492 9.42 7.26
37 33192620–33193912 x 32.79 6.5
*38 33372651–33375048 x x x x x x x x 10.93 8.76
39 33389687–33392295 x x x 2.3 7.51
40 29830203–29832660 6.08 7.77
41 29889483–29892066 21.2 4.15
42 29937894–29939594 38.78 2.48
43 30484481–30486798 96.59 1.04
44 30491424–30493923 1.4 2
45 30526624–30528439 x x 3.54 7.33
46 30527803–30529467 x x 3.54 6.73
47 30534798–30537070 42.42 1.26
48 30881555–30884300 98.55 4.27
49 31092038–31094660 74.72 7.51
50 31270669–31273172 x x 4.59 2.75
51 31454436–31456982 8.59 5.84
*52 32590480–32591619 44.47 2.11
53 32622631–32625110 91.09 5.97
54 33132309–33134479 x 24.37 1.01
55 33450625–33452501 84.66 2.88
A total number of 55 non-redundant tDMRs were identified. tDMR co-ordinates on chromosome 6 are provided. tDMRs 1–39 are intragenic and 40–55 intergenic. 
Enrichment of genomic features, including CpG islands, DNAseI sites, TSSs, ECRs, CTCF binding sites, RNA PolII binding sites, histone marks (H4K20me1, H3K4me2, 
H3K4me3, H3K36me3, H3K4me1) and H2AZ was tested and marked by symbol 'x' if enrichment was statistically significant (P < 0.05). Percent CpG and repeat density were 
also determined and are shown for each tDMR. tDMRs 14 – 30 (intragenic) and 51 (intergenic) are mapping to the region encoding for C4A and C4B genes. Asterisks indicate 
the tDMRs that overlap with Affy_U95 expression array probes.
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database [41]. This database contains whole-genome
mRNA expression data obtained using human U95A
Affymetrix microarray chips [42] and mRNA extracted
from a number of tissues, including liver, placenta and
CD8+ lymphocytes (sperm was not included in this data-
base). We identified 7 probes on the U95A Affymetrix
array that overlap with tDMRs identified in our liver ver-
sus placenta, liver versus CD8+ lymphocytes and
CD8+lymphocytes versus placenta comparisons. Genomic
features of these tDMRs are shown in Table 2 (see below).
One of the probes (Affymetrix ID 40766_at that corre-
sponds to C4A and C4B transcripts) shows a high inverse
correlation between expression and methylation at these
loci (Figure 6). Both loci are highly expressed and
hypomethylated in liver.
35 out of the 90 identified tDMRs were observed in more
than one comparison. Hence there are 55 loci (average
size 2 kb) within the MHC region that according to this
tDMRs within the MHC regionFigure 4
tDMRs within the MHC region. Pair-wise comparisons (six in total) of the MHC array-derived DNA methylation profiles 
were performed using t-statistics. A threshold of p-value < 0.001 was used. In total 90 tDMRs were identified. Vertical axis 
shows the log2 ratio of the two corresponding methylation profiles. Each line represents a tDMR (average size 2 kb). Black lines 
represent tDMRs that are more methylated in sample 1 of the comparison and grey boxes represent tDMRs that are more 
methylated in sample 2 of the comparison (the identities of the pair-wise comparisons are given on the right). The majority of 
tDMRs are present in comparisons with sperm. The locations of HEP amplicons, a track of the C+G content and the approxi-
mate positions of the MHC class I, II and II subregions and some landmark genes are also indicated. Class III region encoding for 
the C4 genes seems to be less methylated in liver.Page 10 of 16
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tDMR validationFigure 5
tDMR validation. Six tDMRs were randomly selected and subjected to bisulphite sequencing analysis. a). tDMR status based 
on pair-wise comparisons of the log2 MeDIP enrichment ratios of the indicated tissues/cell types. Black boxes represent tDMRs 
that are more methylated in sample 1 of the comparison and grey boxes represent tDMRs that are more methylated in sample 
2 of the comparison. b). Absolute DNA methylation values of individual CpG sites in tDMRs based on bisulphite sequencing 
analysis. Because of assay and or technical limitations, bisulphite data could only be obtained for about 50% of the CpG sites 
involved in the putative tDMRs. Each square represents a CpG site. The colour code indicates methylation values as calculated 
by ESME (see Methods). Grey squares indicate CpG sites for which no data could be obtained. Based on this analysis, bisulphite 
data essentially agree with array data in all cases. Numbers of tDMRs correspond to tDMR numbers in table 2.
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Example of tDMRs correlating with tissue-specific gene expressionFigure 6
Example of tDMRs correlating with tissue-specific gene expression. a) tDMRs within the region encoding the C4A 
and C4B genes. Vertical axis shows the log2 ratio of the two corresponding methylation profiles. Grey lines indicate regions 
(average size 2 kb) that are less methylated in liver compared to the other samples (placenta, sperm, CD8). Known genes and 
Affy_U95 expression array probes within this region are also shown. b). Expression of C4A and C4B. Graph shows the mean 
expression values of the probe corresponding to C4A and C4B (Affy_ID: 40776_at) transcripts in three samples tested: CD8, 
liver, placenta. C4A and C4B transcripts are highly expressed in liver tissue only. Data were taken from the GNF SymAtlas 
[41].
BMC Medical Genomics 2008, 1:19 http://www.biomedcentral.com/1755-8794/1/19study shows tissue-specific methylation levels. We define
these 55 loci as non-redundant tDMRs (to reflect the non-
redundancy at the sequence level) and show their
genomic locations in Figure 7 and Table 2. The high den-
sity of 18 non-redundant tDMRs within the C4 comple-
ment region is clearly visible. To characterize their
potential functionality, the 55 non-redundant tDMRs
were analyzed for a number of genomic features using the
ENSEMBL functional build [43]. The result of this analysis
is summarized in Table 2. We found the majority (39) of
these tDMRs to map to intragenic regions and the minor-
ity (16) to map to intergenic regions. While repetitive ele-
ments were overrepresented within the intergenic tDMRs
(44%), DNAse I sites and evolutionary conserved ele-
ments (ECRs) were overrepresented within the intragenic
tDMRs (15%). Furthermore, only 2% of the tDMRs con-
tained transcription start sites (TSS) and about 7% CpG
islands and RNA polymerase II binding sites. In all, 21%
of the tDMRs contained features significantly (P < 0.05)
associated with regulation, such as CpG islands, DNase1
and RNA polII binding sites, TSSs and ECRs. Although
only few other epigenetic data are yet publicly available
for the MHC, we also analyzed the tDMRs for features
associated with epigenetic function. Based on this analy-
sis, 6 (11%) tDMRs have insulator protein (CTCF) bind-
ing sites [44], 13 correlated with the transcription-
activating histone marks (H3K4me2, H3K36me3,
H3K4me3 and H3K4me1) and two with the transcrip-
tion-silencing mark H4K20me1 [6]. Interestingly, 54% of
the H3K4me3 sites overlapping with both intragenic and
intergenic tDMRs appeared to be close to DNaseI sites.
Finally, two tDMRs were associated with the histone vari-
ant H2AZ [45].
Discussion
The array reported here is the first high-resolution (2 Kb)
genomic tiling array of the entire MHC. Commercially
available tiling arrays usually exclude repeat sequences
and therefore cover only about 50% of the genomic
sequence. Previous whole-genome tiling arrays [25] that
included the MHC were constructed from P1 artificial
chromosomes (PACs) and bacterial artificial chromo-
somes (BACs), resulting in a resolution of approximately
100 Kb. By utilizing a public clone resource [27], our array
could be generated at a fraction of the costs associated
with commercial arrays, albeit at lower resolution than is
achievable with these platforms. The array is compatible
with standard array processing and scanning platforms
and contains 7832 features of which about 97% can be
expected to be informative according to our quality con-
trol procedures. Upon request, the MHC array is freely
available from the Microarray Facility at the Wellcome
Trust Sanger Institute [39].
To demonstrate utility, we used the array for DNA meth-
ylation profiling of four samples used for the HEP study:
two tissues (liver and placenta), CD8+ lymphocytes and
sperm. Comparison of these profiles allowed us to iden-
tify 55 putative, non-redundant tDMRs (90 in total).
From these, we randomly selected 10% (6 tDMRs) for val-
idation by an independent method. In all cases, tDMR sta-
tus could be confirmed, indicating that the array is
suitable for DNA methylation analysis. While the analysis
carried out here is informative with respect to differential
methylation between samples, it did not allow assigning
absolute DNA methylation values to each tDMR. This is
not a shortcoming of the array but a limitation of the
MeDIP assay which is highly dependent on CpG density
as illustrated in Figure 1. Therefore, it was not possible to
compare our data directly with the HEP data which, in any
case, only cover about 2.5% of the MHC. The on-going
development of a novel algorithm employing a Bayesian
de-convolution strategy to normalize MeDIP array data
for CpG density is likely to overcome this current limita-
tion in the near future (T. Down et al., personal commu-
nication). For the same reason as mentioned above, the
limited number of samples did not allow us to analyse the
data for inter-individual variation which was observed in
the HEP study [20].
Finally, we correlated gene-associated tDMRs with expres-
sion data of the cognate genes available from the GNF
SymAtlas. We found a strong correlation within the region
encoding for instance the fourth component of the
human complement (C4). C4 is an essential factor of the
innate immunity and consists of two isoforms (C4A and
C4B) that differ only in five nucleotides [46]. C4A and
C4B are examples of copy number variants (CNVs) in the
human genome. We show that regions within the 5'-UTR,
3'-UTR and the gene body of C4A and C4B are less meth-
ylated in liver than in sperm, placenta and CD8+ lym-
phocytes. As these two genes are expressed only in liver, it
is possible that DNA methylation is the underlying mech-
anism controlling their expression. At this point, sensitiv-
ity and specificity should also be considered. While
sensitivity is not an issue in this case (the experimental
design normalizes for the genotype of the sample DNA),
specificity is. As neither our array nor the Affymetrix U95
array can discriminate between C4A and C4B (which are
more than 99% identical), it was not possible to ascertain
whether or not these two loci are differentially methylated
in this case. Selective hypermethylation is a known mech-
anism for silencing of duplicated genes [47].
Conclusion
We have generated and validated a genomic tiling array
that can be used to analyse genetic and epigenetic features
of the MHC. We demonstrated its utility for DNA methyl-
ation profiling and the identification of tDMRs. Based onPage 13 of 16
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Non-redundant tDMRs within the MHC regionFigur  7
Non-redundant tDMRs within the MHC region. a). Screen-shot showing the locations of 55 non-redundant tDMRs iden-
tified in the MHC region after uploading of the data to the UCSC genome browser. Each vertical black line represents a puta-
tive tDMR. The high density of 18 tDMRs within the C4A and C4B complement region is clearly visible (boxed with red doted 
line). Tracks showing C+G content, Ensembl genes, CpG islands and conservation are also shown. b). Enlargement of the C4A 
and C4B complement region showing the 18 overlapping or adjacent tDMRs (delimited by red dotted lines) which could be 
part of one large tDMR spanning the entire C4 complement region.
BMC Medical Genomics 2008, 1:19 http://www.biomedcentral.com/1755-8794/1/19our experience, we expect the array to be suitable for a
number of assays (e.g. aCGH, ChIP-chip and expression
analysis) relevant to medical genomics and are currently
in the process of applying it to investigate the down-regu-
lation of HLA class I molecules, a phenotype commonly
associated with cancer [48].
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